Investigating how cancer cells resist targeted therapies
Official title: The kinase inhibited RTK forms a scaffold to drive therapeutic resistance in cancer
Funded at Ut Southwestern Medical Center · NIH-11098393 · Data updated 2026-11-12
This study is looking at how some cancer cells manage to keep growing even when treated with targeted therapies, and it aims to find new ways to help patients get better by understanding these resistance mechanisms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $449,196 |
| NIH project number | 1R01CA299152-01 |
| Project ID | NIH-11098393 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cancers that are treated with targeted therapies, particularly those who have experienced or are at risk of developing resistance to these treatments.
✕Less likely to help
Patients with cancers that do not involve receptor tyrosine kinases or those who are not receiving targeted therapies may not benefit from this research.
What this research studies
This research focuses on understanding how certain cancer cells develop resistance to targeted therapies that inhibit receptor tyrosine kinases (RTKs). It examines both genetic changes and adaptive responses in cancer cells that allow them to survive despite treatment. By studying the mechanisms behind this resistance, the research aims to identify new strategies to overcome these challenges and improve treatment outcomes for patients. The approach includes analyzing the signaling pathways and molecular changes that occur in response to therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that prevent or overcome resistance, improving survival rates for patients.
How similar studies have gone: Previous research has shown success in understanding resistance mechanisms in cancer therapies, indicating that this approach is built on established findings.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Habib, Amyn — Ut Southwestern Medical Center
- Study coordinator: Habib, Amyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.